logo

Actinium Pharmaceuticals Inc (ATNM)



Trade ATNM now with
  Date
  Headline
6/15/2021 9:04:08 AM Actinium :Phase 3 SIERRA Trial Data Shows 100% Bone Marrow Transplant Engraftment In Patients Treated With Iomab-B
6/15/2021 8:46:47 AM Actinium Announces Highlighted Safety Data From Its Ongoing Pivotal Phase 3 SIERRA Trial
6/3/2021 9:42:41 AM Actinium Announces Several Presentations From The Phase 3 SIERRA Study Of Iomab-B
3/25/2021 9:01:06 AM Actinium Completes Enrollment Of Second Dose Cohort In Actimab-A Venetoclax Combination Trial
3/24/2021 7:32:04 AM Actinium Initiates Patient Enrollment In Iomab-ACT Trial For Targeted Conditioning Prior To CD19 CAR T-Cell Therapy
3/3/2021 7:02:17 AM Actinium Appoints Mark Kubik As Chief Business Officer
2/11/2021 7:20:13 AM Actinium Showcases Conditioning Program With 2 Oral Presentations Highlighting Iomab-B And Pivotal Phase 3 SIERRA Trial
1/13/2021 7:01:47 AM Actinium Announces Research Collaboration With Astellas Pharma
12/29/2020 8:31:06 AM Actinium Reports Successful Pre-Planned Ad Hoc Interim Analysis Of Phase 3 SIERRA Trial
12/8/2020 8:09:38 AM Actinium Reveals Promising Data In Actimab-A Venetoclax Combination Trial In Relapsed And Refractory AML
12/7/2020 8:36:25 AM Actinium Presents Interim Data From Pivotal Phase 3 Trial In Patients With R/R AML
12/7/2020 8:18:48 AM Actinium Presents Ongoing Pivotal Phase 3 SIERRA Trial Of Iomab-B In Patients With R/R AML
12/7/2020 7:05:25 AM Actinium Presents Interim Data From Actimab-A CLAG-M Phase 1 Combination Trial At ASH
12/1/2020 7:02:37 AM Actinium Appoints Mary Mei Chen As VP Of Clinical Development
11/23/2020 7:05:38 AM Actinium Highlights Foundational Patents Covering Composition Of Apamistamab And Iomab-B And Recent EU Patent Activity